This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ATL-1251
Description: Renzapride is both a 5-HT4 receptor full agonist (which acts as a pro-kinetic, enhancing motility) and a 5-HT3 receptor antagonist (which can reduce pain and diarrhea). This dual mode of action is unique and gives renzapride the potential to normalize bowel function rather than move from one extreme of constipation or diarrhea to the other.
Deal Structure: Renzapride was initially discovered at Beecham Research Laboratories and was licensed from SmithKline Beecham in 1998 by Alizyme for use in the treatment of IBS. As a result of the merger between GlaxoWellcome and SmithKline Beecham to form GlaxoSmithKline, Alizyme acquired all rights to renzapride in 2000.
Additional information available to subscribers only: